Results: 1-11 |
Results: 11

Authors: Holz-Smith, SL Sun, IC Jin, L Matthews, TJ Lee, KH Chen, CH
Citation: Sl. Holz-smith et al., Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIVactivity of the betulinic acid derivative IC9564, ANTIM AG CH, 45(1), 2001, pp. 60-66

Authors: Chen, CH Jin, L Zhu, CB Holz-Smith, S Matthews, TJ
Citation: Ch. Chen et al., Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate, J VIROLOGY, 75(14), 2001, pp. 6700-6704

Authors: Matthews, TJ Denney, PA
Citation: Tj. Matthews et Pa. Denney, Digital imaging of surgical specimens using a wet scanning technique, J CLIN PATH, 54(4), 2001, pp. 326-327

Authors: Chen, CH Greenberg, ML Bolognesi, DP Matthews, TJ
Citation: Ch. Chen et al., Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41, AIDS RES H, 16(18), 2000, pp. 2037-2041

Authors: Lawless-Delmedico, MK Sista, P Sen, R Moore, NC Antczak, JB White, JM Greene, RJ Leanza, KC Matthews, TJ Lambert, DM
Citation: Mk. Lawless-delmedico et al., Heptad-repeat regions of respiratory syncytial virus F-1 protein form a six-membered coiled-coil complex, BIOCHEM, 39(38), 2000, pp. 11684-11695

Authors: Salmon-Ceron, D Excler, JL Finkielsztein, L Autran, B Gluckman, JC Sicard, D Matthews, TJ Meignier, B Valentin, C El Habib, R Blondeau, C Raux, M Moog, C Tartaglia, J Chong, P Klein, M Milcamps, B Heshmati, F Plotkin, S
Citation: D. Salmon-ceron et al., Safety and immunogenicity of a live recombinant canarypox virus expressingHIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection, AIDS RES H, 15(7), 1999, pp. 633-645

Authors: Gorse, GJ Corey, L Patel, GB Mandava, M Hsieh, RH Matthews, TJ Walker, MC McElrath, MJ Berman, PW Eibl, MM Belshe, RB
Citation: Gj. Gorse et al., HIV-1(MN) recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1(MN) recombinant glycoprotein 120 vaccine, AIDS RES H, 15(2), 1999, pp. 115-132

Authors: Rovinski, B Dekaban, GA Cao, SX Yao, FL Persson, R Matthews, TJ Klein, MH
Citation: B. Rovinski et al., Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguishedfrom HIV-1 infectees, VIROLOGY, 257(2), 1999, pp. 438-448

Authors: LaBranche, CC Hoffman, TL Romano, J Haggarty, BS Edwards, TG Matthews, TJ Doms, RW Hoxie, JA
Citation: Cc. Labranche et al., Determinants of CD4 independence for a human immunodeficiency virus type 1variant map outside regions required for coreceptor specificity, J VIROLOGY, 73(12), 1999, pp. 10310-10319

Authors: Vu, HM Myers, D de Lorimier, R Matthews, TJ Moody, MA Heinly, C Torres, JV Haynes, BF Spicer, L
Citation: Hm. Vu et al., Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: Relation to specificity of peptide-induced anti-HIV neutralizing antibodies, J VIROLOGY, 73(1), 1999, pp. 746-750

Authors: Hoxie, JA LaBranche, CC Endres, MJ Turner, JD Berson, JF Doms, RW Matthews, TJ
Citation: Ja. Hoxie et al., CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2, J REPRO IMM, 41(1-2), 1998, pp. 197-211
Risultati: 1-11 |